Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.
Frequently Asked Questions
What is market cap of Evotec SE - ADR?
The market cap of Evotec SE - ADR is $3.41B
What is the 52 week high for Evotec SE - ADR?
The 52 week high for Evotec SE - ADR is $16.46.
What is the 52 week low for Evotec SE - ADR?
The 52 week low for Evotec SE - ADR is $7.80.
What is Evotec SE - ADR stock price today?
Evotec SE - ADR' stock price today is $9.63.
What is the pe ratio of Evotec SE - ADR?
The PE ratio of Evotec SE - ADR is -17.40.
What is the price to book ratio of Evotec SE - ADR?
The price to book ratio of Evotec SE - ADR is 2.8278.
What is the 50-day moving average of Evotec SE - ADR?
The 50-day moving average of Evotec SE - ADR is 9.5425.